Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II
about
Less Is More: Substrate Reduction Therapy for Lysosomal Storage DisordersBrain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model.The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activationEffects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Glycosaminoglycan storage disorders: a reviewMucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse ModelA genetic model of substrate reduction therapy for mucopolysaccharidosis.The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patientsEmerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.Gene expression-targeted isoflavone therapy.Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.Treatment options for lysosomal storage disorders: developing insights.Current and potential therapeutic strategies for mucopolysaccharidoses.Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Nanotechnology applied to treatment of mucopolysaccharidoses.Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells.Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice.Effects of different doses of soy isoflavones on bone tissue of ovariectomized rats.Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).Effects of soy isoflavones and mechanical vibration on rat bone tissue.Genistein supplementation in patients affected by Sanfilippo disease.Ovariectomy alters energy metabolism in rat striatum: effect of supplementation with soy diet rich in isoflavones.
P2860
Q26744230-5CFFD736-1242-4A39-91B2-4CE9E2EAE01DQ33755372-AA31C5A8-89C5-4859-B360-55DA8A7459DDQ33761283-2B984C4E-C93D-403C-9438-B6D2538EDA19Q34626878-9052A53D-1207-445B-8C95-39F5A8CA7B66Q35367599-D3F0CE74-FC10-44D7-8DB9-474741F4C73EQ35571515-0A7E08BF-2D07-47CF-9282-90399391CF0DQ35661233-8F94EB39-F18E-4535-8171-8FD7052DECBBQ35795405-E5EF4800-250A-40BF-9682-E4A88475DCA8Q36332885-4D61C4D3-6022-40A8-98C8-77851781C940Q36433464-5C5A4FC4-87A3-483E-ACB6-8A4225ED4492Q36516376-3320EF3B-5B72-4885-80C4-438C718719C6Q37876354-E638C1AC-CB86-4E69-8B14-C6B793DE4713Q37987877-8C4F42DD-807C-40E1-8382-E6961A395547Q38040710-A5BFFE72-EA4D-4A7C-ABD6-73400DFBA60DQ38046227-831AD29E-4286-42F0-A4B9-61540413908EQ38194635-A660CC2E-2CD7-46DE-87AA-D7C48C075438Q38634722-C5CC5B91-F951-4674-BC99-493A4D768DEDQ38850942-551BAE8F-B49B-412F-B3B7-D415DCBE11B3Q39060517-FE12474F-DD92-40BE-9984-D18D7EB5D1C8Q39546149-6C4369C1-1DB2-4395-829E-9BEEA20BF1ADQ41969965-A74B3259-927A-4329-AB91-3E201256D39FQ43585847-5B902EF6-4243-45DC-8E63-64828694C190Q45874778-25453EA0-7461-45D1-8189-E9297E42B63AQ46489443-17284B2D-625D-4153-B111-5FA1532DA098Q48674391-EF519AA0-C6D7-4C03-9B11-889CB5B66E06Q51533016-53AE884B-73DD-4569-B457-BF9A0CAAC49A
P2860
Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@ast
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@en
type
label
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@ast
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@en
prefLabel
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@ast
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@en
P2093
P2860
P1476
Genistein reduces glycosaminog ...... mucopolysaccharidosis type II
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2009.00565.X
P407
P577
2010-02-05T00:00:00Z